Skip to main navigation

Main Corporate Nav

  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Partnering
    • Our History
  • Pipeline
    • Overview
    • AL Amyloidosis & Birtamimab
    • Parkinson's Disease & Prasinezumab
    • ATTR Amyloidosis & PRX004
    • Alzheimer's Disease
    • Pioneering Neuroscience
    • Publications
  • Clinical Trials
    • Overview
    • Birtamimab Phase 3 Study
    • Prasinezumab Phase 2 Study
    • PRX004 Phase 1 Study
    • Expanded Acces Policy
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial & Filings
    • Corporate Governance
    • Stock information
    • Analyst Coverage
  • Careers
    • Overview
    • Our Values
    • Compensation & Benefits
    • Opportunities
    • Public House
  • Contact Us
    About Us
    • Leadership
    • Board of Directors
    • Partnering
    • Our History
    • About Us
      • Management
      • Board of Directors
      • Partnering
      • Our History
    • Pipeline
      • Parkinson’s Disease & prasinezumab
      • ATTR Amyloidosis & PRX004
      • Alzheimer’s Disease
      • Neuroscience Discovery Programs
      • Publications
    • Clinical Trials
      • Prasinezumab Phase 2 Study
      • PRX004 Phase 1 Study
      • Expanded Access Policy
    • Investors
      • Press Releases
      • Events & Presentations
      • Financials & Filings
      • Corporate Governance
      • Stock Information
      • Analyst Coverage
    • Careers
      • Our Values
      • Compensation & Benefits
      • Opportunities
      • Public House
    • Contact Us
    • Menu Menu

    SEC Filing Details

    Investor Relations

    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
      • Key Ratios
      • Irish Statutory Financial Statements
    • Corporate Governance
      • Committee Composition
    • Stock Information
    • Analyst Coverage

    Shareholder Tools

    SEC Filing Details

    Document Details

    Form
    8-K
    Filing Date
    Mar 20, 2018
    Document Date
    Mar 20, 2018
    Form Description
    Report of unscheduled material events or corporate event
    Filing Group
    Current Reports
    Company
    Prothena Corporation plc
    Issuer
    PROTHENA CORP PUBLIC LTD CO

    Filing Formats

    View HTML
    Download PDF
    Download DOC
    Download XLS

    Main Corporate Nav

    • About Us
      • Overview
      • Leadership
      • Board of Directors
      • Partnering
      • Our History
    • Pipeline
      • Overview
      • AL Amyloidosis & Birtamimab
      • Parkinson's Disease & Prasinezumab
      • ATTR Amyloidosis & PRX004
      • Alzheimer's Disease
      • Pioneering Neuroscience
      • Publications
    • Clinical Trials
      • Overview
      • Birtamimab Phase 3 Study
      • Prasinezumab Phase 2 Study
      • PRX004 Phase 1 Study
      • Expanded Acces Policy
    • Investors
      • Overview
      • Press Releases
      • Events & Presentations
      • Financial & Filings
      • Corporate Governance
      • Stock information
      • Analyst Coverage
    • Careers
      • Overview
      • Our Values
      • Compensation & Benefits
      • Opportunities
      • Public House
    • Contact Us

    2021© Prothena | Terms of Use | Privacy Policy

    Scroll to top